Global Poultry Vaccine Market Size, Segmentation, Trends and Growth Analysis Forecast by 2030

Poultry Vaccine Market Overview and Analysis:

The Poultry Vaccine Market is currently valued at USD 1.56 billion in the year 2022 and is expected to register a CAGR of 5.32% over the forecast period 2022-2030.

Get Complete Analysis Of The Report - Download Free Sample PDF

Poultry Vaccines help prevent any particular disease by boosting the poultry animals’ immune system to produce antibodies, which fight against organisms. Their use in poultry production avoids or minimizes the emergence of clinical disease at the farm level, thus increasing production.

The growth is primarily attributed to the rising demand for poultry health coupled with the increasing poultry headcount and increasing prevalence of zoonotic diseases in poultry. Furthermore, the growing consumption of meat globally, initiatives taken by the government, growing demand for poultry-related food products, the latest technologies for manufacturing new vaccines, and the increasing poultry healthcare expenditure are the factors that are fueling the growth of the global poultry vaccines market.

Poultry Vaccine Market Latest Trends:

The growing product R&D, rising incidence of diseases in poultry, demand to secure food sources, and awareness and initiatives to curb antimicrobial resistance are some of the key drivers of this market. Further developments are contributing to market growth. For instance, in 2019, HIPRA extended its coccidiosis vaccine lineup with the launch of EVANT - an attenuated vaccine for broilers.

Segmentation:

The poultry vaccines market is segmented

By Diseases

• Bronchitis 
• Avian Influenza 
• Newcastle Disease 
• Marek's Disease
• Other Diseases 

By Technology

• Recombinant Vaccines
• Inactivated Vaccines
• Live Attenuated Vaccines (LAV)
• Others

Geography

• North America
• Europe
• Asia-Pacific
• Middle East
• Africa
• South America

The report offers the value (in USD million) for the above segments.

For Detailed Market Segmentation - Download Free Sample PDF

Drivers:

Increasing Incidences of Poultry and Zoonotic Diseases

Avian influenza poses a risk to public health insofar as all avian influenza viruses are potentially transmissible to humans. For instance, WHO reported that in August 2023, a total of 244 cases of human infection with avian influenza A(H5N1) virus have been reported from four countries within the Western Pacific Region. The same source also reported that globally, from January 2003 to 14 July 2023, 878 cases of human infection with avian influenza A(H5N1) virus were reported from 23 countries. Of these 878 cases, 458 were fatal. Thus, such instances are increasing the demand for poultry vaccines thereby contributing to the studied market growth over the forecast period.

In addition, it is detrimental to animal health and welfare, and it has serious economic consequences for the poultry sectors affected, from the farming sector to the businesses that depend on it downstream. In recent years, the majority of European countries, and a large number of countries worldwide, have been affected by epidemics of highly pathogenic avian influenza (HPAI). The current epizootic is the most severe seen in Europe in recent history. Thus, farmers must get their poultry animals regularly checked and diagnosed. Therefore, the increasing burden of poultry and zoonotic diseases is driving the global poultry vaccine market is expected to grow during the forecast period of the study.

R&D Developments in Poultry Vaccines

The growing R&D activities, particularly in the field of poultry vaccination are fuelling the growth of the studied market. For instance, in July 2019, Ceva acquired IDT Biologika GmbH’s veterinary biopharmaceutical as well as R&D business. The strong synergies that exist between the two companies’ swine and poultry vaccine range and Ceva’s global geographic footprint will allow rapid expansion of the sales of the current IDT product range to the rest of the world. Thus, such developments are fueling the studied market growth over the forecast period.

Restraints:

Use of Counterfeit Medicine and Increasing Costs of Animal Testing and Veterinary Services

A counterfeit poultry medicine's content is often substandard, containing fewer or no active ingredients or incorrect measures.  Using such medicines may harm the health of poultry thereby affecting productivity that may directly cause huge losses to farmers, thereby slowing down the studied market growth. Furthermore, a study published by NCBI reported that the average cost for poultry vaccines ranges around USD 20 - USD 50 and this is quite costly for the farmers living in developing countries, thereby slowing down the growth of the studied market.

COVID-19 Impact on the Poultry Vaccine Market 

The COVID-19 pandemic has created opportunities for vaccine manufacturers that can be leveraged to gain market share. This is owing to the growing awareness regarding animal diseases, demand for safe food stock and products, and concerns over zoonoses. For instance, in 2021, the Annual report published by MSD reported that the company’s revenue registered a growth of 17% in FY2021 to USD 48,704 million compared to USD 41,518 million in FY2020 and its animal health Segment of MSD registered revenue was USD 5,568 million in 2021 as compared to USD 4,703 million in 2020. Thus, initially, the studied market’s growth was hampered due to lockdown the restriction, but with the ease of government restriction, the market is expected to witness significant growth over the forecast period.

Segmental Analysis:

Newcastle Disease Segment is Expected to Witness Significant Growth over the Forecast Period

In January 2020, Boehringer Ingelheim launched the VAXXITEK HVT+IBD+ND vaccine, to protect poultry against Newcastle Disease, Marek’s Disease, and Infectious Bursal Disease (classic and variant types). Thus, such developments are fueling the growth of the studied market.

Recombinant Vaccines Segment is Expected to Witness Significant growth Over the Forecast Period

The innovation in recombinant poultry vaccines is driving the growth of the studied market, as recombinant poultry vaccines eliminate the possibility of interference with maternal immunity and/or other vaccines and the possibility of vaccine viruses becoming latent in vaccinated birds. Swollen eyes are a clear symptom of ILT infection in poultry. Fowlpox virus and herpesvirus recombinant vaccines are widely used in the poultry industry. For example, one vector is fowlpox virus, into which Newcastle disease virus HA and F genes are incorporated. It has the benefit of conferring immunity against the fowlpox virus as well.

North America is Expected to Witness Significant Growth Over the Forecast Period

North American poultry vaccine is expected to have a significant share in the worldwide market over the forecast period, owing to the factors, such as the increase in consumption of poultry-derived products, growing consumer awareness regarding food safety, and increasing incidence of zoonotic diseases associated with poultry. Also, in North America advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. This is likely to fuel the market growth over the forecast period.

Get Complete Analysis Of The Report - Download Free Sample PDF

Competitive Analysis:

The market players in the poultry vaccines market are involved in various growth strategies such as collaborations, partnerships, agreements, mergers, and acquisitions to enhance the market presence. A few key players in the market are

• Bio-Vet
• Boehringer Ingelheim
• Ceva Animal Health
• Elanco
• Merck & Co.
• Phibro Animal Health Corporation
• Venkys
• Zoetis Inc.

Recent Developments:

1) In March 2023:  France launched a tender for 80 million doses of bird flu vaccines to be ready to start its vaccination programme in the autumn. The announcement came after French health and safety agency ANSES endorsed the government's plan to vaccinate millions of poultry birds against bird flu, setting out three scenarios for the campaign.

2) In December 2022: Animal healthcare player Hester Biosciences Ltd will develop and commercialise the low pathogenic avian influenza inactivated vaccine for poultry. The company has signed an agreement to acquire the indigenously-developed technology from the Indian Council of Agricultural Research - National Institute of High-Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry. 

Frequently Asked Questions (FAQ) :

Q1. How big is the Poultry Vaccine Market ?

Q2. What is the market size of the Poultry Vaccine Market ?

Q3. Which Region is expected to hold the highest Market share ?

Q4. Which are the major companies in the Poultry Vaccine Market ?